John Maraganore (Scott Eisen/Bloomberg via Getty Images)

Bob Nelsen woos John Maraganore to his first VC post af­ter re­tir­ing from Al­ny­lam

Af­ter al­most two decades of pri­mar­i­ly be­ing known as Al­ny­lam’s CEO, John Maraganore is get­ting a new, promi­nent ti­tle.

Maraganore is among a slate of new ven­ture part­ners at ARCH Ven­ture, join­ing along­side ex-FDA of­fi­cial Lu­ciana Bo­rio, Jake Bauer (pre­vi­ous­ly at MyoKar­dia), Ax­el Bou­chon (for­mer head of Leaps by Bay­er) and Sabah Oney (of Alec­tor fame).

The move was hard­ly sur­pris­ing. Maraganore has made it clear that his re­tire­ment, which is sched­uled for the end of the year, sig­naled a shift in­to a new phase of his ca­reer where, in­stead of hands-on par­ent­ing, he want­ed to be like a “grand­fa­ther” to the next gen­er­a­tion of biotech star­tups, im­part­ing hard-earned wis­dom about the treach­er­ous jour­ney from the lab to mar­ket — one he per­son­al­ly shep­herd­ed Al­ny­lam and its RNAi sci­ence through.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.